Carmine N. Stengone insider trades: Contineum Therapeutics (CTNM) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Carmine reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | CTNM | ↓ Sell | 2,500 | $16.46 | $41K | Direct | Sep 8, 2026 (0d) |
| Aug 3, 2026 | CTNM | ↓ Sell | 2,500 | $16.01 | $40K | Direct | Aug 3, 2026 (0d) |
| Jul 8, 2026 | CTNM | ↓ Sell | 2,500 | $16.00 | $40K | Direct | Jul 8, 2026 (0d) |
| Jun 30, 2026 | CTNM | ↓ Sell | 10,000 | $16.01 | $160K | Direct | Jul 1, 2026 (1d) |
| Feb 25, 2026 | CTNM | ↓ Sell | 7,100 | $16.02 | $114K | Direct | Feb 26, 2026 (1d) |
| Sep 11, 2024 | KPRX | ↑ Buy | 1,250 | $3.68 | $5K | Direct | Sep 12, 2024 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CTNM insiders
Open-market trades in the last 12 months
About Carmine N. Stengone's insider trades
Carmine N. Stengone is CEO and President at Contineum Therapeutics (CTNM). Since Sep 11, 2024, Carmine has reported 1 open-market purchase worth $5K and 5 sales worth $395K on SEC Form 4. In the last 12 months: 5 sales ($395K).
Their filings also include grants and awards (7 filings), option exercises (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CTNM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.